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Background: The St Gallen International Expert Consensus 2011 has proposed a new classification system for
breast cancer. The purpose of this study was to elucidate the relationship between the breast cancer subtypes
determined by the new classification system and genomic characteristics.
Methods: Invasive breast cancers (n = 363) were immunohistochemically classified as follows: 111 (30.6%) as luminal
A, 95 (26.2%) as luminal B (HER2 negative), 69 (19.0%) as luminal B (HER2 positive), 41 (11.3%) as HER2, and
47 (12.9%) as basal-like subtypes.
Results: The high expression of Ki-67 antigen was detected in 236 tumors; no cases of luminal A subtype showed
high expression of the Ki-67 antigen, but more than 85% of tumors of the other subtypes showed high expression.
In addition, DNA ploidy and chromosomal instability (CIN) were assessed using imaging cytometry and FISH,
respectively. In this series, 336 (92.6%) tumors consisted of 129 diploid/CIN- and 207 aneuploid/CIN + tumors.
Diploid/CIN- and aneuploid/CIN+ features were detected in 64.9% and 27.9% of luminal A, 41.1% and 49.5% of
luminal B (HER2-), 11.6% and 81.2% of luminal B (HER2+), 4.9% and 90.2% of HER2, and 17.0% and 76.6% of
basal-like subtypes, respectively. Unlike the luminal B (HER2+), HER2 and basal-like subtypes, the luminal A and
luminal B (HER2-) subtypes were heterogeneous in terms of DNA ploidy and CIN.
Conclusions: It is reasonable to propose that the luminal A and luminal B (HER2-) subtypes should be further
divided into two subgroups, diploid/CIN- and aneuploid/CIN+, based on their underlying genomic status.Background
Breast cancer is one of the most common malignant
tumors in the world, and a large number of patients die
of the disease every year. Morphologically and biologic-
ally, breast cancer is a heterogeneous disease family
comprising a number of subtypes [1]. Although the con-
ventional histological classification system is indispens-
able for the accurate histological diagnosis of breast
cancer, it does not always provide sufficient information
to evaluate the biological characteristics of individual tu-
mors and it is not useful for treatment selection. Indeed,
it is well known that tumors with the same histological
subtypes can have very different biological trajectories.* Correspondence: kohsuke@yamaguchi-u.ac.jp
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distribution, and reproduction in any mediumThis situation indicates the need for a more reliable clas-
sification system, which guides clinical decision-making
such as the determination of an optimal therapeutic
strategy for individual cancer patients [2,3]. Determining
the status of estrogen and progesterone receptors, HER2
amplification and Ki-67 antigen expression is practical
and valuable for estimating the patient prognosis and for
determination of the treatment strategy [4]. Recently, the
St Gallen International Expert Consensus proposed a
new intrinsic biological classification system based on
the expression of the estrogen receptor (ER), progester-
one receptor (PgR), HER2 and Ki-67 [5]. The classifica-
tion system categorizes invasive breast carcinomas into
the following five distinct molecular subtypes; luminal A,
luminal B (HER2-), luminal B (HER2+), HER2, and basal-
like subtypes, and these subtypes are linked to the thera-
peutic selection [5]. The classification can be performedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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panel of markers is possible, and this approach is de-
signated as the IHC-based classification [6,7]. The clin-
ical value of this classification system is still ongoing
world wide.
The biological characteristics of a tumor are primarily
affected by genomic changes. In this context, the nuclear
DNA content has been measured to estimate the bio-
logical characteristics of solid tumors including breast
cancer, and in general, it is accepted that DNA aneu-
ploid cancers represent a poorer prognosis than diploid
tumors [8-13]. However, the new classification system
has not been evaluated with regard to the status of DNA
ploidy and/or CIN. The relationship between the ICH-
based subtypes and the status of DNA ploidy and CIN
should be elucidated to better understand the differences
in the biological characteristics within and between sub-
types as a precondition to achieve personalized treat-
ment for breast cancer, and the ICH-based classification
system should be evaluated in terms of the status of
DNA ploidy and CIN.
In this study, the DNA ploidy and CIN were compared
with the subtypes classified by the IHC-based classifica-




This study evaluated 363 primary invasive breast can-
cers. None of the patients had any family history of her-
editary breast cancer. The average age of patients was
56.9 years, ranging from 30 to 87 years old. Patients had
received neither chemotherapy nor radiation prior to
surgery. The Institutional Review Board for Human Use
at Yamaguchi University Graduate School of Medicine
approved the study protocol, and informed consent for
this study was obtained from all patients. Representative
parts of the surgically removed tumor tissues were used
for touch-smear preparations before fixation. Tumor tis-
sue specimens were fixed in 10% formalin overnight and
were subjected to histological examinations including
the nuclear grade. An immunohistochemical analysis
was performed to classify the breast cancers into mo-
lecular subtypes (IHC-based subtypes) [5]. The touch-
smear preparations were subjected to fluorescence in
situ hybridization (FISH) and laser scanning cytometry
(LSC) to evaluate the genomic instability status and
DNA ploidy, respectively [14].
Immunohistochemistry (IHC)
The expression status of the ER, PgR, HER2, and Ki-67
antigen was evaluated by an immunohistochemical ana-
lysis with antibodies against the ER (1D5, 1:50 dilution,
Dako, Denmark), PgR (PR88, no dilution, BioGenex, SanRamon, CA), and Ki-67 antigen (MIB-1, 1:100 dilution,
DAKO) in formalin-fixed, paraffin-embedded tissue
serial sections as previously described [14]. Prior to im-
munohistochemical staining, antigen retrieval was per-
formed with microwave heating of tissue sections in a
citrate buffer solution at pH 6.0. A cut-off value of 1%
for both receptors was used to classify the expression of
ER and PgR according to criteria proposed by `The Japa-
nese Society of Breast Cancer’ [15] and others [4,16,17].
When immunostaining was observed in more than 1%
of tumor nuclei, the tumor was considered to be positive
for the ER or PgR. In brief, breast cancers were classified
into five subtypes as follows: luminal A (ER+, PgR+ or
PgR-, HER2-, and low Ki-67 index), luminal B (HER2 -)
(ER+, PgR+ or PgR-, HER2-, and high Ki-67 index), Lu-
minal B (HER2+) (ER+, PgR+ or PgR-, and HER2+),
HER2 (ER-, PgR-, and HER2+), and basal-like (ER-, PgR-,
andHER2-).
The expression of Ki-67 antigen was scored for the per-
centage of tumor cell nuclei with positive immunostaining
above the background level by observing at least 1000
tumor cell nuclei (Ki-67 index). In this study, the Ki-67
index was scored as high when 14% or more of the tumor
cells were immunostained according to the guidelines of
the `St Gallen International expert Consensus’ [5]. All
tumors were scored as either high or low according to the
Ki-67 index. The immunostained slides were evaluated in-
dependently by two of the authors (K. I. and T. F.).
CIN assessed by FISH
Chromosomal instability (CIN) was examined by FISH
using four pericentromeric probes (chromosomes 7, 11,
17, and 18 for D7Z1, D11Z1, D17Z1, and D18Z1, re-
spectively; Abbott Laboratories, Abbott Park, Illinois, IL)
on the touch-smear preparations as previously described
[18-20], and the presence or absence of CIN was de-
termined according to the degree of variations in the
number of FISH spots between nuclei [20-22]. Slides
were counterstained with 4’6-diamidino-2-phenylindole
(DAPI). CIN was considered to be positive when the
fraction of cells with a modal chromosome number was
less than 75% for four chromosomes [18-22]. HER2
amplification was tested on the smear preparations for
IHC equivocal cases using a PathVysion HER2 DNA
Probe Kit (Abbott Laboratories) according to the
manufacturer’s instructions as described previously. A
tumor was considered to be as positive for HER2
gene amplification when the HER2/CEP 17 ratio was
2.2 or higher.
Determination of DNA ploidy by LSC
Measurement of the nuclear DNA content by LSC was
performed as described previously [20,21]. Briefly, the
touch-smear preparations fixed in 70% ethanol were
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containing 0.1% RNase (Sigma-Aldrich Co., St Louis,
MO). The DNA content was measured by a laser scan-
ning cytometer (LSC 101; Olympus). Usually, more than
5,000 cells were examined in each sample. A DNA histo-
gram was generated, and the DNA ploidy was deter-
mined. DNA ploidy was expressed as the DNA index
(DI). A case with 1.0≤ DI <1.2 was classified as a diploid
and all others were classified as aneuploid tumors.Statistical analysis
The differences in the frequency of marker expression
frequency between two groups were determined using
the Chi-square test. A difference was considered to be
significant for P-values <0.05.Results
IHC-based classification
Of the 363 breast cancers, 258 (71.1%) were ER positive
and 218 (60.1%) were PgR positive. In this series, 47
(12.9%) tumors were triple-negative (ER and PgR nega-
tive expression and no HER2 amplification). The expres-
sion of the Ki-67 antigen was deemed positive in 237
(65.3%) tumors (Ki-67+) (Figure 1). HER2 was positive
in 110 (30.3%) tumors, which were classified into either
the luminal B or HER2 subtype.IHC-based subtype classification
According to the recent criteria [5], breast cancers were
classified into five IHC- based subtypes as follows: 111
(30.6%) as the luminal A subtype, 95 (26.2%) as the lu-
minal B (HER2-) subtype, 69 (19.0%) as the luminal B
(HER2+) subtype, 41 (11.3%) as the HER2 subtype, and
47 (12.9%) for as basal-like (Table 1).IHC-based subtypes and Ki-67 antigen expression
The high expression of Ki-67 antigen was detected in
237 (65.3%) tumors: 0 (0%) of the luminal A tumors, 95
(100%) of the luminal B (HER2-) tumors, 59 (85.5%) of
the luminal B (HER2+) tumors, 40 (97.6%) of the HER2
tumors, and 43 (91.5%) of the basal-like tumors (Table 1).
The average Ki-67 index was 5.8% (±3.6 standard devi-
ation) for the luminal A subtype, 24.3% (±9.8) for the lu-
minal B (HER2-) subtype, 31.0% (±15.8) for the luminal
B (HER2+) subtype, 43.0% (±19.6) for the HER2 subtype,
and 46.4% (±23.1) for the basal-like subtype. The aver-
age Ki-67 index was significantly different between the
luminal A and the other subtypes (P = 7.366×10-12,
P = 4.662×10-12, P = 4.061×10-10, and P = 7.779×10-4 be-
tween the luminal A subtype and luminal B (HER2- &
HER2+), HER2, and basal-like subtypes, respectively)
(Figure 2).DNA ploidy
The DNA indices (DIs) ranged from 1.0 to 3.34 in this
series of breast cancers. According to the DIs, the 363
breast cancers were divided into two groups, 144 diploid
(1.0 ≤DI <1.2) and 219 aneuploid (DI≥ 1.2) tumors.
Chromosomal instability (CIN)
In this series, 140 (38.6%) tumors were classified as CIN
negative (CIN-), and 223 (61.4%) were classified as CIN
positive (CIN+) according to the size of the variant frac-
tion in the chromosome copy number. In this series,
92.8% of the 223 CIN+ tumors were aneuploid, and
94.5% of the 219 aneuploid tumors were CIN+. In con-
trast, 92.1% of the 140 CIN- tumors were diploid, and
89.6% of the 144 diploid tumors were CIN-.
DNA ploidy and CIN
Diploid/CIN- features were detected in 129 (35.5%) of
breast tumors and aneuploid/CIN- features were de-
tected in 207 (57.0%) tumors, respectively. In this study,
92.6% of the breast cancers were divided into two
groups, 129 diploid/CIN- and 207 aneuploid/CIN+
tumors.
IHC-based subtypes, DNA ploidy and CIN
The diploid/CIN- status was detected in 72 (64.9%) of
the 111 luminal A carcinomas, 39 (41.1%) of the 95 lu-
minal B (HER2-) carcinomas, 8 (11.6%) of the 69 lu-
minal B (HER2+) carcinomas, 2 (4.9%) of the 41 HER2
carcinomas, and 8 (17.0%) of the 26 basal-like carcin-
omas. The frequency of diploid/CIN- tumors was higher
in the luminal A carcinomas than in luminal B (HER2-),
luminal B (HER2+), HER2, and basal-like carcinomas
(P = 6.315×10-4, P = 2.690×10-12, P = 5.133×10-11, and P =
3.823×10-8 between luminal A subtype and luminal B
(HER2-), luminal B (HER2+), HER2, and basal-like sub-
types, respectively) (Figure 3). In contrast, the aneu-
ploid/CIN+ status was detected in 31 (27.9%) of the 111
luminal A, 47 (49.5%) of the luminal B (HER2-), 56
(81.2%) of the 69 luminal B (HER2+), 37 (90.2%) of 41
HER2, and 36 (76.6%) of the 47 basal-like subtype
tumors. The frequency of aneuploid/CIN+ tumors was
lower in luminal A subtypes than in luminal B (HER2-),
luminal B (HER2+), HER2, and basal-like subtypes (P =
1.482×10-3, P= 3.962×10-12, P=6.996×10-11, P= 1.525×10-8
between luminal A subtype and luminal B (HER2-), HER2
(HER2+), HER2, and basal-like subtypes, respectively)
(Figure3).
In this series, 41.1% and 49.5% of luminal B (HER2-)
subtype cases showed diploid/CIN- and aneuploid/CIN+
features , respectively. The proportion of diploid/CIN-
and aneuploid/CIN+ in luminal B (HER2-) was similar to
that in all tumors, in which the percentage of diploid/CIN-
and aneuploid/CIN+ was 35.5% and 57.0%, respectively
Figure 1 The results of the immunohistochemical analysis evaluating the expression status of the ER, PgR, and Ki-67 antigens, FISH
detecting HER2 amplification, and the histological features in conventional tissue sections stained with hematoxylin-eosin. Upper rows:
A case of invasive ductal carcinoma classified into the luminal A subtype. The ER was expressed in 100% of the tumor cells, and the PgR was
expressed in 90% of them. No HER2 amplification was detected (green and red spots indicate chromosome 17 centromeres and HER2). The Ki-67
antigen was expressed in 1% of the cells in this tumor (Ki-67 index = 1%). Lower rows: A medullary carcinoma was classified into the basal-like
subtype. The ER and PgR are apparently not expressed in any of the tumor cells. No HER2 amplification was detected. The Ki-67 antigen was
expressed in 70% of the tumor cells (Ki-67 index = 70%).
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fications were very rare.IHC-based subtypes, grade, and DNA ploidy/CIN
This breast cancer series included 78 grade1, 69 grade 2,
and 206 grade 3 tumors. Grade 1 tumors were detected
in 47.7% of the 111 luminal A subtype tumors, 15.8% of
the 95 luminal B (HER2-) subtype tumors, 8.7% of the
69 luminal B (HER2+) subtype tumors, 0% of the 41
HER2 subtype tumors, and 8.5% of the 47 basal-like sub-
type tumors (Figure 4). Of the grade1 tumors 67.9%
were categorized as being the luminal A subtype. Grade
3 tumors were detected in 18.0% of luminal A subtype
tumors, 58.9% of luminal B (HER2-), 75.4% of luminal B
(HER2+) subtypes, 92.7% of HER2 subtypes, and 85.1%
of the basal-like subtype tumors (Figure 4).Grade 1 tumors were detected in 54 (41.9%) of the 129
diploid/CIN- cancers and 19 (9.2%) of the 207 aneu-
ploid/CIN+ cancers. In contrast, grade 3 tumors were
detected in 35 (27.1%) of the diploid/CIN- cancers and
161 (77.8%) of the aneuploid/CIN+ cancers. Diploid/
CIN- and aneuploid/CIN+ features were found in 69.2%
and 24.4% of grade 1 tumors, respectively. Diploid/CIN-
and aneuploid/CIN+ features were found in 17.0% and
78.2% of grade 3 tumors, respectively (Figure 5).
Discussion
Recently, a molecular classification system was proposed
to categorize breast cancers into subtypes associated
with the optimal therapeutic modality, and it has be-
come widely used [5]. In this study, the genomic status
together with the cell proliferation activity was com-
pared between IHC-based subtypes.
Table 1 The status of genomic and cell proliferation markers in the ICH-based subtypes
Markers LumWalA Luminal B, HER2- Luminal B, HER2+ HER2 Basal-hke Total
No. of tumors 111 (30.6%) 95 (26.2%) 69 (19.0%) 41 (11.3%) 47 (12.9%) 363
Age (range) 58.6 (34–84) 54.8 (27–84) 54.7 (30–78) 58,9 (38–87) 56.8 (31–84) 56.7
Ki-67c14% 111 (100%) 0 (0%) 10 (14.5%) 1 (24.3%) 4 (8.5%) 126 (34.7%)
K6714% 0 (0%) 95 (100%) 59 (85.5%) 40 (97.8%) 43 (91.5%) 237 (65.3%)
DiploEd 78 (70.3%) 44 (46.3%) 11 (15.9%) 3 (7.3%) 8 (17.0%) 140 (38.6%)
Aneuploid 33 (29.7%) 51 (53.7%) 58 (84.1%) 38 (92.7%) 39 (83.0%) 223 (61.4%)
CIN- 74 (66.7%) 43 (45.3%) 10 (14.5%) 3 (7.3%) 10 (21.3%) 140 (38.6%)
CIN. 37 (33.3%) 52 (54.7%) 59 (85.5%) 38 (92.7%) 37 (787%) 223 (61.4%)
DipIod!ClN- 72 (64.9) 39 (41.1%) 8 (11.6%) 2 (4.9%) 8 (17.0%) 129 (35.5%)
AneuplodiClN+ 31 (27.9%) 47 (49.5%) 56 (81.2%) 372 (90.2%) 36 (76.6%) 207 (57.0%)
Grade 1 53 (47.7%) 15 (15.8%) 6 (8.7%) 0 (0%) 4 (8.5%) 78 (20.4%)
Grade 2 32 (28.8%) 23 (24.2%) 10 (14.5%) 2 (4.9%) 2 (4.3%) 69 (19.0%)
Grade 3 20 (18.0%) 56 (58.9%) 52 (58.9%) 38 (92.7%) 40 (85.1%) 206 (57.3%)
nd 6 1 1 1 1 10
The numbers in the table indicate the number of tumors fitting each item. The numbers in parenthesis are the percentages of tumors fitting each hem. Ki-67+;
tumors with a high Ki-67 index, Ki-67-; tumors with a ow Ki-67 index, CIN-; the absence of chromosomal instability, CIN+; the presence of chromosomal instability,
Dip/CIN-IKi-67+; tumors with diploidiClN -IKi-67- features, Aneup/CIN/Ki-67; tumors.
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been a matter of controversy because of interlaboratory
variations, the Ki-67 index has been used to divide
breast cancers into tumors with low and high prolifera-
tion activity [5,16,23,24]. The expression level of the Ki-Figure 2 The relationship between the Ki-67 indices and
subtypes. The high expression (Ki-67 index≧14%) of the Ki-67
antigen was detected in 237 of the 363 breast cancers. The average
Ki-67 index was 5.8% (±3.6 standard deviation) for the luminal A
subtype, 24.3% (±9.8) for the luminal B (HER2-) subtype, 31.0%
(±15.8) for the luminal B (HER2+) subtype, 43.0% (±19.6) for the
HER2 subtype, and 46.4% (±23.1) for the basal-like subtype. The
difference in the average Ki-67 index was statistically significant
between the luminal A and other subtypes (P = 7.366×10-12,
P = 4.662×10-12, P = 4.061×10-10, and P = 7.779×10-4 between luminal
A subtype and luminal B (HER2- & HER2+), HER2, and basal-like
subtypes, respectively).67 antigen was generally connected with the IHC-based
subtypes [25]. Not surprisingly, all luminal A subtype
tumors showed a low Ki-67 index. In contrast, more
than 85% of luminal B, HER2 and basal-like subtypes
had a high Ki-67 index. It has been suggested that the
cell proliferation activity is much lower in luminal A tu-
mors than in other subtypes. The cell proliferation activ-
ity as well as other cellular characteristics such as the
HER2 expression is a useful marker for categorizing breast
cancer, and it is primarily affected by the genomic status.
Determination of DNA ploidy in individual tumors is
a simple method to examine crude changes in the gen-
ome, but it is very informative. Although aneuploidy and
CIN phenotype are different by definition [26,27], almost
all aneuploid breast cancers in the present study dis-
played CIN+ features and vice versa in agreement with
previous reports [20,21,27,28]. Smid and colleagues
reported that in particular the basal-like subtype showed
the CIN+ feature [28]. The majority (93.4%) of breast
cancers were divided into either diploid/CIN- or aneu-
ploid/CIN+ tumors. The aneuploid/CIN+ status was the
major underlying phenotype in the luminal B (HER2+),
HER2, and basal-like subtypes. Approximately 80% of
tumors with diploid/CIN- features were of either the
luminal A or luminal B (HER2-) subtypes, and a con-
siderable number of aneuploid/CIN+ tumors were also
included in these two subtypes. These observations in-
dicate that luminal A and luminal B (HER2-) subtypes
can be differentiated from other subtypes based on
their underlying genomic changes.
The genomic changes detected by array-based CGH
were obviously different between diploid/CIN- and
Figure 4 The relationship between the nuclear grade and
subtypes. Grade 1 tumors were detected in 47.7% of the 111
luminal A subtype tumors, 15.8% of the 95 luminal B (HER2-)
subtypes, 8.7% of the 69 luminal B (HER2+) subtypes, 0% of the 41
HER2 subtypes, and 8.5% of the 47 basal-like subtype tumors. Of the
grade1 tumors 67.9% were categorized as part of the luminal A
subtype. Grade 3 tumors were detected in 18.0% of luminal A
tumors, 58.9% of luminal B (HER2-), 75.4% of luminal B (HER2+),
92.7% of HER2, and 85.1% of basal-like tumors. In the HER2 and
basal-like subtypes, grade3 tumors were common but grade 1
tumors are rare. In contrast, the luminal A and luminal B (HER2-)
subtypes consisted of heterogeneous populations with different
grade. Solid square; grade 1 tumors, cross; grade 2 tumors, and solid
circle; grade 3 tumors.
Figure 3 The relationship of subtypes to the DNA ploidy and
CIN. The diploid/CIN- status was detected in 72 (64.9%) of the 111
luminal A carcinomas, 39 (41.1%) of the 95 luminal B (HER2-)
carcinomas, 8 (11.6%) of the 69 lumminal B (HER2+) carcinomas, 2
(4.9%) of the 41 HER2 carcinomas, and 8 (17.0%) of the 26 basal-like
carcinomas. In contrast, the aneuploid/CIN + status was detected in
31 (27.9%) of the 111 luminal A, 47 (49.5%) of the luminal B (HER2-),
56 (81.2%) of the 69 luminal B (HER2+), 37 (90.2%) of the 41 HER2,
and 36 (86.6%) of the 47 basal-like subtype tumors. The incidence of
diploid/CIN- and aneuploid/CIN+ status was different between the
luminal A subtype and luminal B (HER2-), luminal B (HER2+), HER2,
and basal-like subtypes (p = 0.0006, p = 5E-13, p = 5E10-12, and
p= 8E10-9). In addition, the incidence of diploid/CIN- and
aneuploid/CIN+ status was statistically different between the luminal
B (HER2-) subtype and luminal B (HER2+), HER2, and basal-like
subtypes (p = 0.00002, p = 0.000009, and p= 0.002). Black bar;
diploid/CIN- tumors, gray bar; aneuploid/CIN+ tumors, white
column; others.
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[28]. DNA ploidy and the CIN status are linked to the
cell proliferation activity [29-31]. In addition, aneuploid
and CIN+ features are associated with a high prolifera-
tion activity and poor prognosis when compared to dip-
loid and CIN- tumors [32]. The DNA ploidy and CIN
status were different between luminal B (HER2+), HER2,
and basal-like subtypes and the remaining two subtypes.
As mentioned above, more than 75% of luminal B
(HER2+), HER2 and basal-like subtypes showed aneu-
ploid/CIN+ features . In contrast, 41.1% and 49.5% of
the luminal B (HER2-) subtype showed diploid/CIN-
and aneuploid/ CIN+ features , respectively. The propor-
tion of diploid/CIN- and aneuploid/CIN+ tumors in the
luminal B (HER2-) subtype was similar to that in all tu-
mors. This similarity proves that the luminal B (HER2-)
subtype can be further divided into subgroups based on
the underlying genomic status. Thus, both luminal A
and luminal B (HER2-) subtypes can be divided into two
subgroups, diploid/CIN- and aneuploid/CIN+, based on
the genomic characteristics of the tumors. Since an-
euploid and/or CIN+ tumors show a poorer prognosis
[8-13,33,34], the further classification of luminal A andluminal B (HER2-) subtypes may be useful for estimating
the prognosis of patients with breast cancer and for clin-
ical decision-making. Further studies are necessary to
evaluate the additional classification based on these fea-
tures. The relationship between CIN and patient prog-
nosis depends on the status of ER expression in breast
cancers, paradoxical relationship between CIN and pa-
tient prognosis in ER- breast cancers was recently re-
ported [35,36]. LuminalA and luminal B (HER2-) subtypes,
which were focused in this study, are ER+ by definition.
The conventional nuclear grading system allows for a
rough estimation of the prognosis for breast cancer
patients [37]. The nuclear grade of tumor cells can be
used as a surrogate marker of the Ki-67 index in the
new classification system [5]. In this series, more than
85% of the HER2 and basal-like subtype tumors repre-
sented features of grade 3 cancer, whereas the luminal A
and luminal B (HER2-) subtypes consisted of mixture of
tumors with different grades. The nuclear grade was
linked with the DNA ploidy and CIN status. It could be
said that the luminal A and luminal B (HER2-) subtypes
were heterogeneous both genomically as well as pheno-
typically. Thus, it is therefore reasonable to propose that
the luminal A and luminal B (HER2-) subtypes should
Figure 5 The differences in the nuclear grades between
diploid/CIN- and aneuploid/CIN+ breast cancers. Grade 1 tumors
were more frequently seen in diploid/CIN- carcinomas than in
aneuploid/CIN+ carcinomas (p = 1.601×10-12). In contrast, grade 3
tumors were much more common in aneuploid/CIN+ tumors than
in diploid/CIN- tumors (p = 5.285×10-20). The incidence of grade 2
tumors was significantly different between these two types of
tumors with different genomic characteristics (P = 2.281×10-3). White
column; grade 1 tumors, gray column; grade 2 tumors, and black
column; grade 2 tumors.
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aneuploid/CIN+, based on their underlying genomic
status.Conclusions
Unlike the luminal B (HER2+), HER2 and basal-like sub-
types, the luminal A and luminal B (HER2-) subtypes
were heterogeneous in terms of DNA ploidy and CIN.
Thus, it is reasonable to propose that the luminal A and
luminal B (HER2-) subtypes should be further divided
into two subgroups, diploid/CIN- and aneuploid/CIN+,
based on their underlying genomic status.
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